NCT04897958View on ClinicalTrials.gov

Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

CompletedOBSERVATIONAL
Enrollment

14,417

Participants

Timeline

Start Date

September 21, 2019

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

Degarelix dispensing claim is used as the reference group.

DRUG

Leuprolide

Leuprolide dispensing claim is used as the exposure group.

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT04897958 - Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter